Lineage Cell Therapeutics Inc
$ 1.55
-0.64%
24 Apr - close price
- Market Cap 386,086,000 USD
- Current Price $ 1.55
- High / Low $ 1.58 / 1.54
- Stock P/E N/A
- Book Value 0.18
- EPS -0.28
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -1.05 %
- 52 Week High 2.09
- 52 Week Low 0.43
About
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Analyst Target Price
$4.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | 0.0035 | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 |
| Estimated EPS | -0.0457 | -0.02 | -0.03 | -0.028 | -0.03 | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Surprise | 0.0492 | -0.11 | -0.1 | 0.008 | 0.02 | 0.02 | 0.02 | 0 | 0.01 | 0 | 0.01 | 0.01 |
| Surprise Percentage | 107.6586% | -550% | -333.3333% | 28.5714% | 66.6667% | 50% | 40% | 0% | 25% | 0% | 25% | 25% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.02 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.3125 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LCTX
2026-04-16 19:09:53
This article identifies three promising penny stocks—Niagen Bioscience (NAGE), Strata Critical Medical (SRTA), and Lineage Cell Therapeutics (LCTX)—from the US market. It highlights their financial health, growth potential, and recent developments. Niagen Bioscience shows strong profitability and strategic partnerships, Strata Critical Medical demonstrates significant revenue growth despite unprofitability, and Lineage Cell Therapeutics is advancing cell replacement therapies with no debt, despite current losses.
2026-04-15 17:09:53
This article highlights three promising penny stocks for investor consideration: Niagen Bioscience (NAGE), Strata Critical Medical (SRTA), and Lineage Cell Therapeutics (LCTX). It provides an overview of each company's financial health, operations, and market capitalization, emphasizing their growth potential and outlining key financial metrics and strategic developments. The article suggests that while penny stocks carry risks, an informed selection based on strong financials can offer significant value.
2026-04-14 06:39:26
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) has announced the formation of a Scientific Advisory Board (SAB) to guide the development of its cell transplant pipeline. Dr. Joachim Fruebis, an executive with vast experience in ophthalmology, neurology, and diabetes, is the founding member. Additionally, Lineage appointed Dr. Priyantha Herath as Senior Vice President and Head of Clinical Operations, bringing extensive clinical and regulatory expertise in neurodegenerative diseases.
2026-04-14 05:40:39
Lineage Cell Therapeutics has announced the formation of a Scientific Advisory Board and the appointment of a new Senior Vice President and Head of Clinical Operations. These appointments follow a significant 215% return for the company over the past year, though its shares are currently considered overvalued by InvestingPro. The company, which develops allogeneic cell therapies, also recently filed for a potential share offering and received a reiterated Buy rating from H.C. Wainwright.
2026-04-13 19:39:45
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) has announced the formation of a Scientific Advisory Board (SAB) to guide the development of its cell transplant pipeline, built on the AlloSCOPEâ„¢ platform. Dr. Joachim Fruebis, a distinguished executive with expertise in various therapeutic areas including ophthalmology and neurology, has been named the founding member. Additionally, Lineage announced the appointment of Priyantha Herath, M.D., Ph.D., as Senior Vice President and Head of Clinical Operations, bringing extensive experience in neurology and clinical development to the company.
2026-04-10 14:09:23
The article highlights the growing longevity biotech market, projected to reach $29.7 billion by 2034, as companies like Avaà Bio, Inc. (AVAI) are developing cell-based and gene therapies to target the drivers of aging. Avaà Bio, through its joint venture Klothonova, is working on an α-Klotho anti-aging therapy using genetically modified, encapsulated cells to restore longevity protein levels. Other companies such as Lineage Cell Therapeutics (LCTX), Ocugen (OCGN), Vertex Pharmaceuticals (VRTX), and Longeveron (LGVN) are also making significant advancements in cell and gene therapies for age-related conditions.
